Prostate cancer patients could be screened to detect aggressive tumours after scientists identified a protein linked to severe forms of the disease.
Patients with high levels of the protein NAALADL2 are more likely to need surgery, chemotherapy or radiotherapy while those with low concentrations could be spared unnecessary treatment, researchers said.
Michael E. Williams, MD
Nonresponse to Rituximab in Immune Thrombocytopenia
David Green, MD, PhD
Single- vs. Multiple-Fraction Radiotherapy for Bone Metastases
Robert Dreicer, MD, MS, FACP
Panitumumab Ineffective for Colorectal Cancers with Rare RAS Mutations
David H. Ilson, MD, PhD
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
William J. Gradishar, MD
Breast Cancer Chemoprevention for BRCA1 and BRCA2 Carriers
William J. Gradishar, MD
Smoldering Multiple Myeloma: Dousing the Fire?
Michael E. Williams, MD
David Green, MD, PhD
Switching from a Vitamin K Antagonist to Rivaroxaban Appears to Be Safe
Joel M. Gore, MD